Trial · NCT06215118
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
NCT06215118, Phase 1, Active not recruiting, Pfizer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30). Trials, record NCT06215118. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06215118
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
- NCT number
- NCT06215118
- Status
- Active not recruiting
- Phases
- Phase 1
- Enrollment
- 100 participants, actual
- Lead sponsor
- Pfizer
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab, Iberdomide
- First posted
- 2024-01-22
- Last updated
- 2026-09-15
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1: Number of participants with dose limiting toxicity (DLT) | Cycle 1, about 28 days | Dose limiting toxicity rate based on dose limiting toxicity evaluable participants |
| Primary | Part 2: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment | Assessed from baseline up to 90 days after last dose of study treatment | Number of participants with AE among participants who take at least 1 dose of study intervention. AEs are categorized by seriousness and relationship to treatment. Relatedness to study drug is assessed by investigator. |
| Secondary | Part 1: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment | Assessed from baseline up to 90 days after last dose of study treatment | Number of participants with AE among participants who take at least 1 dose of study intervention. AEs are categorized by seriousness and relationship to treatment. Relatedness to study drug is assessed by investigator. |
| Secondary | Part 1 and Part 2: Number of Participants with Adverse Events (AE) characterized by type, frequency, severity | Assessed from baseline up to 90 days after last dose of study treatment | An AE was any untoward medical occurrence in a participant who received study drug without regard to possibly of causal relationship |
| Secondary | Part 1 and Part 2: Number of Participants with Clinically Significant Change from Baseline in Laboratory Abnormalities | Assessed from baseline up to 90 days after last dose of study treatment | Laboratory abnormalities as characterized by type, frequency, severity |
| Secondary | Part 1 and Part 2: Percentage of Participants with Objective Response Rate (ORR) | Assessed for approximately 2 years | Percent of participants having confirmed Stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), or Partial Response (PR) per IMWG criteria as determined by investigator |
| Secondary | Part 1 and Part 2: Percentage of Participants with Complete Response Rate (CRR) | Assessed for approximately 2 years | Percent of participants having Complete Response/ Stringent Complete Response (CR+sCR) per IMWG criteria as determined by investigator |
| Secondary | Part 1 and Part 2: Time to Response (TTR) | Assessed for approximately 2 years | For participants with an objective response per IMWG criteria, TTR is the time from first dose to the first documentation of objective response that is subsequently confirmed |
| Secondary | Part 1 and Part 2: Duration of Response (DOR) | Assessed for approximately 2 years | For participants with an objective response per IMWG criteria, DOR is the time from first documentation of objective response that is subsequently confirmed until the first documentation of confirmed progressive disease (PD) per IMWG criteria |
| Secondary | Part 1 and Part 2: Duration of Complete Response (DOCR) | Assessed for approximately 2 years | For participants with a Complete Response/ Stringent Complete Response (CR+sCR) per IMWG criteria, DOCR is the time from the first documentation of CR/sCR that is subsequently confirmed until the first documentation of confirmed progressive disease (PD) per IMWG criteria |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06215118
GET https://conductscience.org/api/trials/v1/NCT06215118/registered